ClosedPublished 29 Mar 2024

Immunome, Inc. /
Ayala Pharmaceuticals, Inc.

Immunome purchases Ayala Pharmaceuticals assets in completed sale

Buy side: Immunome, Inc.
Buy sideImmunome, Inc.
Target: Ayala Pharmaceuticals, Inc.
TargetAyala Pharmaceuticals, Inc.
Source · 29 Mar 2024Source-verified
Buy side: Immunome, Inc.
Buy sideImmunome, Inc.
Target: Ayala Pharmaceuticals, Inc.
TargetAyala Pharmaceuticals, Inc.
01 / BuyerImmunome, Inc.
02 / TargetAyala Pharmaceuticals, Inc.
Source-verified
01

What happened

Immunome, Inc. completed its purchase of Ayala Pharmaceuticals, Inc.’s assets and liabilities related to the AL101 and AL102 programs. The transaction included $20.0 million in cash, shares of Immunome common stock and specified liabilities assumed by Immunome.

Ayala Pharmaceuticals is a clinical-stage oncology company.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Immunome purchases Ayala Pharmaceuticals assets in completed sale

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

    Source-verified

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request an inviteAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.